argenx NV ADR (ARGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $60.37B
Last updated: Nov 17, 2026 at 11:04 AM ET
argenx NV ADR (ARGX) P/E Ratio & Valuation Multiples
argenx NV ADR (ARGX) trades at 33.5x trailing earnings and 6.1x sales. Its P/S of 6.1x is below its 5-year median of 20.9x. Its forward P/E is 28.8x. The median P/E across 6 similar companies is 24.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 16.3% higher over the next year. Its free cash flow yield is 3.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 33.5x |
| Forward P/E | 28.8x |
| Price to sales | 6.1x |
| Price to book | 178.4x |
| Price to FCF | 33.0x |
| PEG | 1.3 |
| FCF yield | 3.0% |
Historical Medians
Against its 10-year medians, its P/B is 2777.4% above 6.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 6.1x | 20.9x | N/A |
| P/B | 178.4x | 6.5x | 6.2x |
Valuation History
Over the 5 of the 9 year ends shown that have a P/S, its P/S ranged from 13.1x in 2024 to 33.9x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $840.95 | 14.2x | 6.5x |
| 2024 | $615.00 | 13.1x | 7.7x |
| 2023 | $380.43 | 25.3x | 4.9x |
| 2022 | $378.83 | 33.9x | 7.0x |
| 2021 | $350.19 | 22.9x | 6.3x |
| 2020 | $294.09 | N/A | N/A |
| 2019 | $160.52 | N/A | 4.8x |
| 2018 | $96.07 | N/A | 4.7x |
| 2017 | $63.14 | N/A | 3.5x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ARGX
What is ARGX's forward P/E ratio?
argenx NV ADR has a forward P/E ratio of 28.8x.
Is ARGX stock overvalued?
GNG's valuation label for ARGX is Undervalued. Its P/E of 33.5x compares with a median of 24.7x across 6 similar companies.
What is ARGX's price to sales ratio?
argenx NV ADR has a price to sales ratio of 6.1x.
What is ARGX's PEG ratio?
argenx NV ADR has a PEG ratio of 1.3.
ARGX pages: Overview, Valuation, Competitors